Safety and Efficacy of Intrapleural Tissue Plasminogen Activator and DNase during Extended Use in Complicated Pleural Space Infections

Table 2

Outcomes of patients receiving intrapleural therapy.

	Standard IPFT	Extended IPFT	value
Patients ()	81	20
Total number of chest tubes [median [interquartile range (25–75)]]	1 1-1	2 1-2	0.015
Placement of additional chest tube after IPFT initiation ( (%))	12 (15)	7 (35)	0.080
Median outcomes in hospital days [interquartile range (25–75)]
Chest tube duration	6 4–11	8 6–11	0.200
Hospital length of stay	13 9–19	17 9–25	0.355
Admission to lytic cessation	7 5–11	9 5–12	0.281
Admission to surgery day	6 0–14	7 7–14	0.975
Day of surgery to discharge	11 6–21	16 11–22	0.534
Lytic cessation to discharge	4 3–9	3 1–19	0.404
Referral for surgery ( (%))	13 (16)	3 (15)	0.821
Complications (, (%))
Readmission	13 (16)	2 (10)	0.741
Outpatient pleural drainage	10 (12)	2 (10)	0.924
Bleeding	2 (3)	2 (10)	0.365
Tube dislodgement	3 (4)	3 (15)	0.166
New narcotic use	46 (57)	16 (80)	0.056